| scholarly article | Q13442814 |
| P2093 | author name string | N Gupta | |
| I A Khan | |||
| M Majumdar | |||
| A Tiwari | |||
| M Sachdeva | |||
| M Pal | |||
| N Sachdeva | |||
| P2860 | cites work | A guild of 45 CRISPR-associated (Cas) protein families and multiple CRISPR/Cas subtypes exist in prokaryotic genomes | Q21090166 |
| CRISPR Provides Acquired Resistance Against Viruses in Prokaryotes | Q21508827 | ||
| A large-scale RNAi screen in human cells identifies new components of the p53 pathway | Q24319883 | ||
| MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B | Q24564757 | ||
| CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes | Q24625361 | ||
| RNA-guided editing of bacterial genomes using CRISPR-Cas systems | Q24630389 | ||
| Somatic mutations affect key pathways in lung adenocarcinoma | Q24648102 | ||
| A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity | Q24669850 | ||
| Structural basis of PAM-dependent target DNA recognition by the Cas9 endonuclease | Q27684893 | ||
| EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy | Q27824812 | ||
| Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors | Q27851431 | ||
| Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers | Q27851457 | ||
| EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. | Q27851590 | ||
| Cancer statistics, 2015 | Q27860576 | ||
| Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib | Q27861059 | ||
| Met, metastasis, motility and more | Q28235183 | ||
| Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma | Q28250347 | ||
| Transcriptional gene silencing through epigenetic changes mediated by non-coding RNAs | Q28278927 | ||
| Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease | Q28284509 | ||
| RNA-guided gene activation by CRISPR-Cas9-based transcription factors | Q28295458 | ||
| The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA | Q28297640 | ||
| One-Step Generation of Mice Carrying Mutations in Multiple Genes by CRISPR/Cas-Mediated Genome Engineering | Q29547524 | ||
| Cas9–crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria | Q29614420 | ||
| CRISPR--a widespread system that provides acquired resistance against phages in bacteria and archaea | Q29614740 | ||
| CRISPR-Cas systems for editing, regulating and targeting genomes | Q29615781 | ||
| CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering | Q29615783 | ||
| Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression | Q29615784 | ||
| Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity | Q29615792 | ||
| Genome-scale CRISPR-Cas9 knockout screening in human cells | Q29616044 | ||
| Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer | Q29618155 | ||
| CRISPR-Cas9 knockin mice for genome editing and cancer modeling | Q30607892 | ||
| Allele-specific genome editing and correction of disease-associated phenotypes in rats using the CRISPR-Cas platform | Q33851650 | ||
| DNA interrogation by the CRISPR RNA-guided endonuclease Cas9. | Q33931841 | ||
| Efficient genome engineering in human pluripotent stem cells using Cas9 from Neisseria meningitidis | Q34037839 | ||
| Phylogeny of Cas9 determines functional exchangeability of dual-RNA and Cas9 among orthologous type II CRISPR-Cas systems | Q34039072 | ||
| Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers. | Q34043681 | ||
| Aberrant epigenetic landscape in cancer: how cellular identity goes awry | Q34149629 | ||
| Cas3 is a single-stranded DNA nuclease and ATP-dependent helicase in the CRISPR/Cas immune system | Q34166291 | ||
| Protospacer adjacent motif (PAM)-distal sequences engage CRISPR Cas9 DNA target cleavage. | Q34282392 | ||
| The tracrRNA and Cas9 families of type II CRISPR-Cas immunity systems | Q34337685 | ||
| Programmable repression and activation of bacterial gene expression using an engineered CRISPR-Cas system | Q34350509 | ||
| CRISPR-mediated direct mutation of cancer genes in the mouse liver | Q34353586 | ||
| Multiplex CRISPR/Cas9-based genome engineering from a single lentiviral vector | Q34509983 | ||
| Activating human genes with zinc finger proteins, transcription activator-like effectors and CRISPR/Cas9 for gene therapy and regenerative medicine | Q34536068 | ||
| CRISPR: New Horizons in Phage Resistance and Strain Identification | Q34634890 | ||
| Correction of a genetic disease in mouse via use of CRISPR-Cas9. | Q34658184 | ||
| Type I-E CRISPR-cas systems discriminate target from non-target DNA through base pairing-independent PAM recognition | Q34988030 | ||
| FHIT: from gene discovery to cancer treatment and prevention | Q35021334 | ||
| Evaluation of sgRNA target sites for CRISPR-mediated repression of TP53 | Q35421685 | ||
| A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. | Q35791529 | ||
| Efficient inversions and duplications of mammalian regulatory DNA elements and gene clusters by CRISPR/Cas9. | Q35914859 | ||
| Highly parallel identification of essential genes in cancer cells | Q37068513 | ||
| Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system | Q37214501 | ||
| CRISPR/Cas9 systems targeting β-globin and CCR5 genes have substantial off-target activity | Q37271186 | ||
| Potential of DNMT and its Epigenetic Regulation for Lung Cancer Therapy | Q37313424 | ||
| Sequence-specific inhibition of microRNA via CRISPR/CRISPRi system. | Q37541395 | ||
| Enhanced efficiency of human pluripotent stem cell genome editing through replacing TALENs with CRISPRs | Q37585983 | ||
| Memory of viral infections by CRISPR-Cas adaptive immune systems: acquisition of new information | Q38057517 | ||
| Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains | Q38876767 | ||
| Synthesizing AND gate genetic circuits based on CRISPR-Cas9 for identification of bladder cancer cells | Q38942406 | ||
| Sirtuin SIRT6 suppresses cell proliferation through inhibition of Twist1 expression in non-small cell lung cancer. | Q38958874 | ||
| In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by CRISPR/Cas9. | Q38973597 | ||
| DrugTargetSeqR: a genomics- and CRISPR-Cas9-based method to analyze drug targets | Q38984714 | ||
| SGI-110 and entinostat therapy reduces lung tumor burden and reprograms the epigenome | Q39011822 | ||
| The nonsteroidal anti-inflammatory drug NS398 reactivates SPARC expression via promoter demethylation to attenuate invasiveness of lung cancer cells | Q39998314 | ||
| Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. | Q40453775 | ||
| Influence of tumor-associated E-cadherin mutations on tumorigenicity and metastasis | Q40638976 | ||
| Widespread siRNA "off-target" transcript silencing mediated by seed region sequence complementarity | Q41626666 | ||
| Identifying drug-target selectivity of small-molecule CRM1/XPO1 inhibitors by CRISPR/Cas9 genome editing | Q42175237 | ||
| In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system. | Q42183080 | ||
| Inactivation of human SRBC, located within the 11p15.5-p15.4 tumor suppressor region, in breast and lung cancers | Q43787473 | ||
| Targeted mutagenesis in the model plant Nicotiana benthamiana using Cas9 RNA-guided endonuclease | Q43872258 | ||
| Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer | Q44652158 | ||
| Targeted genome modification of crop plants using a CRISPR-Cas system. | Q47822803 | ||
| A chemical genetics approach for the functional assessment of novel cancer genes | Q50595599 | ||
| Phase I study of 5-aza-2′-deoxycytidine in combination with valproic acid in non-small-cell lung cancer | Q50933613 | ||
| Caveolin-1 inhibits breast cancer growth and metastasis | Q57369965 | ||
| Apoptosis induced by depsipeptide FK228 coincides with inhibition of survival signaling in lung cancer cells | Q64377137 | ||
| P433 | issue | 11 | |
| P921 | main subject | lung cancer | Q47912 |
| gene therapy | Q213901 | ||
| CRISPR | Q412563 | ||
| Cas9 | Q16965677 | ||
| P304 | page(s) | 509-517 | |
| P577 | publication date | 2015-10-23 | |
| P1433 | published in | Cancer Gene Therapy | Q15763088 |
| P1476 | title | CRISPR/Cas9: molecular tool for gene therapy to target genome and epigenome in the treatment of lung cancer | |
| P478 | volume | 22 |
| Q58120494 | Blossom of CRISPR technologies and applications in disease treatment |
| Q102063582 | CRISPR-Cas deployment in non-small cell lung cancer for target screening, validations, and discoveries |
| Q26744172 | CRISPR/Cas9 therapeutics: a cure for cancer and other genetic diseases |
| Q91272447 | Cancer therapy with a CRISPR-assisted telomerase-activating gene expression system |
| Q39367664 | Covalent nano delivery systems for selective imaging and treatment of brain tumors |
| Q45863203 | Deletion of the GAA repeats from the human frataxin gene using the CRISPR-Cas9 system in YG8R-derived cells and mouse models of Friedreich ataxia |
| Q26766271 | Emerging Role of Genomic Rearrangements in Breast Cancer: Applying Knowledge from Other Cancers |
| Q55017665 | Epigenetic Targeting of Granulin in Hepatoma Cells by Synthetic CRISPR dCas9 Epi-suppressors. |
| Q45869005 | Expression of PTEN-long mediated by CRISPR/Cas9 can repress U87 cell proliferation. |
| Q28066970 | Genome editing: the road of CRISPR/Cas9 from bench to clinic |
| Q38379632 | Individualized network-based drug repositioning infrastructure for precision oncology in the panomics era. |
| Q92000742 | NCAPG Is a Promising Therapeutic Target Across Different Tumor Types |
| Q49257510 | Network analysis of DEGs and verification experiments reveal the notable roles of PTTG1 and MMP9 in lung cancer |
Search more.